Genmab — Oktober 2019
-
Dr. Hong on Moving Tisotumab Vedotin to Frontline Therapy for Cervical Cancer
https://www.youtube.com/watch?v=SXX_5UNpkak -
CHMP:
The Committee recommended extensions of indication for Darzalex, - so i guess that will be officially approved somewhere next month or so. https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2019 -
-
NYT:GENMAB: EMA-UDVALG UDTALER SIG POSITIVT OM DARZALEX-KOMBINATION
13:19
(Opdateres)CHMP, der er et udvalg under de europæiske sundhedsmyndigheder, EMA, anbefaler, at Genmabs kræftmiddel Darzalex kan blive brugt i kombination med kræftmidlet Revlimid og Dexamethasone til behandling af knoglemarvskræft.
Det fremgår af en fondsbørsmeddelelse fra selskabet fredag middag.
/ritzau/FINANS
Nicoline Lärka Sørensen
RITZAU -
-
Går der ikke et par måneder efter anbfalingen før en eventuel endelig godkendelse udmeldes?
-
Det bliver til jul.
-
I wonder if they are considering a limitation of the indication. We have this problem with Cassiopeia as well as Griffin, that high risk pts don't really benefit from adding dara. In Cassiopeia they do benefit a little, but that is because VTd is a "weaker" combination. In Griffin HR-pts don't benefit at all, as VRd is a better combination. So for 15% of pts it would be waste of money to add dara.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind